PriceTargets.com logo

NASDAQ:ADMA - ADMA Biologics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.80
  • Forecasted Upside: 372.73 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$1.65 As of 04/16/2021 05:00 PM ET
▼ -0.08 (-4.62%)
1 month | 3 months | 12 months
Get New ADMA Biologics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADMA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.80
▲ +372.73% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ADMA Biologics in the last 3 months. The average price target is $7.80, with a high forecast of $11.00 and a low forecast of $6.00. The average price target represents a 372.73% upside from the last price of $1.65.
Buy
The current consensus among 5 contributing investment analysts is to buy stock in ADMA Biologics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/22/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/21/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/19/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/17/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/17/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2021Jefferies Financial GroupReiterated RatingBuy$10.00Low
i
4/1/2021Raymond JamesLower Price TargetOutperform$7.00 ➝ $6.00Low
i
3/26/2021Maxim GroupReiterated RatingBuy$6.00High
i
Rating by Jason McCarthy at Maxim Group
3/26/2021Raymond JamesLower Price TargetOutperform$7.00 ➝ $6.00High
i
1/4/2021HC WainwrightLower Price TargetBuy$12.00 ➝ $11.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
10/1/2020Raymond JamesBoost Price TargetOutperform$7.00 ➝ $9.00High
i
8/6/2020HC WainwrightReiterated RatingBuy$12.00Low
i
Rating by Ram Selvaraju at HC Wainwright
8/6/2020OppenheimerInitiated CoverageBuy$6.00Low
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
7/28/2020HC WainwrightReiterated RatingBuy$12.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/22/2020Maxim GroupInitiated CoverageBuy$6.00N/A
i
5/22/2020HC WainwrightReiterated RatingBuy$12.00N/A
i
Rating by Ram Selvaraju at HC Wainwright
5/7/2020OppenheimerLower Price TargetOutperform$14.00 ➝ $7.00High
i
3/16/2020HC WainwrightLower Price TargetBuy$14.00 ➝ $12.00High
i
Rating by Ram Selvaraju at HC Wainwright
1/8/2020HC WainwrightReiterated RatingBuyLow
i
Rating by Ram Selvaraju at HC Wainwright
11/20/2019HC WainwrightReiterated RatingBuy$13.00Low
i
10/21/2019Maxim GroupSet Price TargetBuy$12.00Low
i
Rating by Jason McCarthy at Maxim Group
8/27/2019Maxim GroupReiterated RatingBuy$12.00High
i
Rating by Jason McCarthy at Maxim Group
8/12/2019Dawson JamesDowngradeBuy ➝ Neutral$4.00High
i
Rating by J. Kolbert at Dawson James
6/25/2019OppenheimerSet Price TargetBuy$14.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
6/4/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$8.00Medium
i
5/23/2019HC WainwrightSet Price TargetBuy$13.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
4/15/2019HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $13.00Low
i
Rating by R. Selvaraju at HC Wainwright
4/4/2019WBB SecuritiesUpgradeBuyLow
i
4/2/2019Maxim GroupSet Price TargetBuy$12.00High
i
Rating by Jason McCarthy at Maxim Group
4/2/2019OppenheimerBoost Price TargetOutperform ➝ Outperform$14.00 ➝ $16.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
2/21/2019HC WainwrightReiterated RatingBuy$10.00Medium
i
Rating by R. Selvaraju at HC Wainwright
2/14/2019Maxim GroupSet Price TargetBuy$12.00Medium
i
Rating by Jason McCarthy at Maxim Group
2/7/2019HC WainwrightReiterated RatingBuy ➝ Buy$10.00High
i
Rating by Jason Kolbert at HC Wainwright
12/20/2018Maxim GroupSet Price TargetBuy ADMA$12.00Low
i
Rating by Jason McCarthy at Maxim Group
12/20/2018OppenheimerSet Price TargetBuy ADMA$13.00Low
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
11/12/2018OppenheimerSet Price TargetBuy$13.00Low
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
11/9/2018HC WainwrightSet Price TargetBuy$17.00High
i
Rating by J. Kolbert at HC Wainwright
10/30/2018HC WainwrightInitiated CoverageBuy$17.00High
i
Rating by J. Kolbert at HC Wainwright
10/17/2018OppenheimerSet Price TargetBuy$13.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
10/17/2018Maxim GroupReiterated RatingBuy$12.00High
i
Rating by Jason McCarthy at Maxim Group
10/12/2018Raymond JamesReiterated RatingBuy$11.00 ➝ $10.00High
i
10/2/2018OppenheimerSet Price TargetBuy$13.00Medium
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
9/5/2018OppenheimerSet Price TargetBuy$13.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
9/5/2018Maxim GroupReiterated RatingBuy$12.00High
i
Rating by Jason McCarthy at Maxim Group
8/13/2018OppenheimerSet Price TargetBuy$13.00Medium
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
8/5/2018OppenheimerSet Price TargetBuy$13.00Low
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
7/30/2018Chardan CapitalInitiated CoverageBuy$10.00Medium
i
Rating by K. Nakae at Chardan Capital
7/26/2018Maxim GroupBoost Price TargetPositive ➝ Buy$10.00 ➝ $12.00Medium
i
Rating by Jason McCarthy at Maxim Group
7/12/2018OppenheimerInitiated CoverageBuy$13.00High
i
Rating by Leland Gershell at Oppenheimer Holdings Inc.
6/13/2018LADENBURG THALM/SH SHLower Price TargetBuy$7.50Low
i
5/14/2018Maxim GroupSet Price TargetBuy$10.00Medium
i
Rating by Jason McCarthy at Maxim Group
4/24/2018Maxim GroupSet Price TargetBuy$10.00Medium
i
Rating by Jason McCarthy at Maxim Group
3/5/2018Maxim GroupSet Price TargetBuy$8.00High
i
Rating by Jason Kolbert at Maxim Group
12/11/2017Maxim GroupReiterated RatingBuy ➝ Buy$13.00 ➝ $8.00Low
i
Rating by Jason McCarthy at Maxim Group
11/14/2017Raymond JamesUpgradeMarket Perform ➝ Outperform$5.00N/A
i
6/28/2017Maxim GroupReiterated RatingBuy$13.00Medium
i
Rating by Jason McCarthy at Maxim Group
6/7/2017Maxim GroupSet Price TargetBuy$13.00Low
i
Rating by Jason McCarthy at Maxim Group
5/15/2017Maxim GroupSet Price TargetBuy$13.00Low
i
Rating by Jason McCarthy at Maxim Group
2/27/2017Maxim GroupSet Price TargetBuy$13.00N/A
i
Rating by Jason Kolbert at Maxim Group
1/23/2017Maxim GroupUpgradeHold ➝ Buy$13.00N/A
i
Rating by Jason Kolbert at Maxim Group
11/14/2016Maxim GroupReiterated RatingHoldN/A
i
Rating by Jason Kolbert at Maxim Group
8/1/2016Raymond JamesDowngradeStrong-Buy ➝ Market PerformN/A
i
8/1/2016Maxim GroupDowngradeBuy ➝ HoldN/A
i
Rating by Jason McCarthy at Maxim Group
7/25/2016Maxim GroupLower Price TargetBuy$24.00 ➝ $14.00N/A
i
Rating by Jason McCarthy at Maxim Group
(Data available from 4/17/2016 forward)
ADMA Biologics logo
ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Read More

Today's Range

Now: $1.65
$1.64
$1.71

50 Day Range

MA: $2.00
$1.67
$2.42

52 Week Range

Now: $1.65
$1.57
$4.20

Volume

2,274,847 shs

Average Volume

3,541,042 shs

Market Capitalization

$200.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.84

Frequently Asked Questions

What sell-side analysts currently cover shares of ADMA Biologics?

The following Wall Street research analysts have issued reports on ADMA Biologics in the last year: HC Wainwright, Jefferies Financial Group Inc., Maxim Group, Oppenheimer Holdings Inc., Raymond James, and Zacks Investment Research.
View the latest analyst ratings for ADMA.

What is the current price target for ADMA Biologics?

5 Wall Street analysts have set twelve-month price targets for ADMA Biologics in the last year. Their average twelve-month price target is $7.80, suggesting a possible upside of 372.7%. HC Wainwright has the highest price target set, predicting ADMA will reach $11.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $6.00 for ADMA Biologics in the next year.
View the latest price targets for ADMA.

What is the current consensus analyst rating for ADMA Biologics?

ADMA Biologics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADMA will outperform the market and that investors should add to their positions of ADMA Biologics.
View the latest ratings for ADMA.

What other companies compete with ADMA Biologics?

Other companies that are similar to ADMA Biologics include Adaptimmune Therapeutics, Orchard Therapeutics, CEL-SCI, Inhibrx, DBV Technologies, Osiris Therapeutics, Harpoon Therapeutics, Vaxart, MeiraGTx, Athira Pharma, Tarsus Pharmaceuticals, Compugen, Solid Biosciences, Agenus and Poseida Therapeutics.

How do I contact ADMA Biologics' investor relations team?

ADMA Biologics' physical mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company's listed phone number is 201-478-5552 and its investor relations email address is [email protected] The official website for ADMA Biologics is www.admabiologics.com.